

## Preferred Drug List Announcement

MO HealthNet Division (MHD) is continuing the state-specific Preferred Drug List (PDL) evaluation process. Drug/Drug classes for review for the upcoming quarter are identified at each of the quarterly meetings of the Drug Prior Authorization Committee and also posted on the Division's web page at <http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf> shortly following each meeting.

MO HealthNet Division's clinical team will conduct the clinical reviews of the drug products under evaluation each quarter. For preferred status consideration for your product, a more detailed review request should be presented to MHD. All clinical information for consideration should be forwarded to Mark Roaseau at [Mark.Roaseau@dss.mo.gov](mailto:Mark.Roaseau@dss.mo.gov) or call (573) 751-6961. These submissions should generally follow the AMCP guideline format. Financial evaluations for these therapeutic class reviews are conducted by Conduent State HealthCare, LLC. Companies wishing to discuss opportunities for supplemental rebates should contact Conduent State HealthCare, LLC at (804) 965-8117.

If you have any questions concerning the PDL submission process, or the policy surrounding the process, feel free to contact the pharmacy program at [MHD.ClinicalServices@dss.mo.gov](mailto:MHD.ClinicalServices@dss.mo.gov) or (573)751-7179. If a public presentation is desired, please contact **Beth Mitchell** at [Beth.A.Mitchell@dss.mo.gov](mailto:Beth.A.Mitchell@dss.mo.gov) or call (573) 751-7179. The Drug PA Committee will convene at **10:00 a.m. on Thursday, June 20, 2019.**

### Drug Therapeutic Class Name

|  |  |
|--|--|
| Amylin Analogs                             | Oral Anti-Diabetics, Alpha-Glucosidase Inh             |
| Antihyperuricemic Agents                   | Oral Anti-Diabetics, Biguanides                        |
| Bile Salts Agents                          | Oral Anti-Diabetics, Combinations                      |
| Bone Deossification Suppression Agents     | Oral Anti-Diabetics, Meglitinides                      |
| BPH Agents                                 | Oral Anti-Diabetics, Sulfonylureas 2 <sup>nd</sup> Gen |
| Cephalosporins and Related, Oral Agents    | Oral Anti-Diabetics, Thiazolidinediones                |
| CAPS Agents                                | Penicillins  |
| DPP-IV Inhibitors                          | SGLT2 Inhibitors                                       |
| Electrolyte Depletors (Phosphate Binders)  | Targeted Immune Modulators                             |
| Fluoroquinolones, Oral Agents              | Tetracyclines  |
| GI Antibiotics, Oral Agents                | Urinary Tract Antispasmodics                           |
| GLP-1 Receptor Agonists                    |  |
| Growth Hormones and Growth Factors         |  |
| Hematopoietic Agents                       |  |
| Hepatitis C Agents                         |  |
| Insulins                                   |  |
| Insulins, Long Acting                      |  |
| Insulins, Mix                              |  |
| Insulins, Rapid Acting                     |  |
| Intravaginal Antibiotics                   |  |
| Macrolides                                 |  |
| Methotrexate Products, Oral and Injectable |  |
| Multiple Sclerosis Agents                  |  |